BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation

  March 3, 2026

   · 

  4 min read
• Press Releases

  Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval

  March 3, 2026

   · 

  5 min read
• Press Releases

  SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments

  March 3, 2026

   · 

  8 min read
• Press Releases

  Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study

  March 3, 2026

   · 

  5 min read
• 

  Complete response letters

  REGENXBIO’s Hunter Rejection Hinged on Inadequate Controls, Surrogate Endpoint

  In a complete response letter published by the FDA on Monday, the agency said a resubmission for REGENXBIO’s Hunter syndrome gene therapy should provide evidence of normalized or improved biomarker levels or neurodevelopmental outcomes.

  March 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  MASH

  Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data

  OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.

  March 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

  March 3, 2026

   · 

  3 min read
• Press Releases

  Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

  March 3, 2026

   · 

  7 min read
• Press Releases

  Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17

  March 3, 2026

   · 

  1 min read
• Press Releases

  Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

  March 3, 2026

   · 

  9 min read